GENMAB AS            DK 1
GENMAB AS DK 1
Share · DK0010272202 · 565131 (XCSE)
Overview Financial Indicators
194,70 EUR
-0,33 % -0,64 EUR
NASDAQ COPENHAGEN A/S (XFRA) · Current prices and charts at MoneyPeak
12.06.2025 06:07

Current Prices from GENMAB AS DK 1

ExchangeTickerCurrencyLast TradePriceDaily Change
XFRA: Frankfurt
Frankfurt
GE9.F
EUR
12.06.2025 06:07
194,70 EUR
199,00 EUR
-2,16 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
-0,75 % 1,04 % 10,00 % 5,07 % -5,26 % -21,01 % -27,24 %

Profil de l'entreprise pour GENMAB AS DK 1 Action

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Fonds investis

Les fonds suivants ont investi dans : GENMAB AS DK 1 investi :

Fonds
iShares MSCI Europe Health Care Sector UCITS ETF EUR (Acc)
Vol. en millions
832,16
Part (%)
1,91 %
Fonds
iShares MSCI Europe Mid Cap UCITS ETF EUR (Acc)
Vol. en millions
1.158,01
Part (%)
1,35 %
Fonds
iShares MSCI Europe Mid Cap UCITS ETF EUR (Dist)
Vol. en millions
110,52
Part (%)
1,35 %
Fonds
iShares Edge MSCI Europe Minimum Volatility UCITS ETF EUR (Dist)
Vol. en millions
175,99
Part (%)
1,14 %
Fonds
iShares MSCI Europe SRI UCITS ETF EUR (Dist)
Vol. en millions
7.713,76
Part (%)
1,10 %

Données de l'entreprise

Nom GENMAB AS DK 1
Société Genmab A/S
Site web https://www.genmab.com
Marché d'origine XCSE NASDAQ COPENHAGEN A/S
WKN 565131
ISIN DK0010272202
Type de titre Action
PDG Dr. Jan G.J. van de Winkel Ph.D.
Capitalisation boursière 11 Mrd.
Pays Danemark
Devise EUR
Employés 2,7 T
Adresse Carl Jacobsens Vej 30, 2500 Copenhagen
Date d'introduction en bourse 2000-10-23

Symboles boursiers

Nom Symbole
Frankfurt GE9.F

Autres actions

Les investisseurs qui détiennent GENMAB AS DK 1 ont également les actions suivantes dans leur portefeuille :
BASF SE
BASF SE Action
CINTAS CORP
CINTAS CORP Action
DEUTSCHE TELEKOM AG
DEUTSCHE TELEKOM AG Action
LPKF LASER+ELECTRON.
LPKF LASER+ELECTRON. Action
MCDONALDS CORP 2045 MTN
MCDONALDS CORP 2045 MTN Obligation
MEDTRONIC PLC
MEDTRONIC PLC Action
NINTENDO CO LTD
NINTENDO CO LTD Action
ORANGE 21/34 MTN
ORANGE 21/34 MTN Obligation
PETROL.BRAS.PFD ADR/2 O.N
PETROL.BRAS.PFD ADR/2 O.N Action
SIXT SE VZO
SIXT SE VZO Action
TSINGTAO BREWERY  H  YC 1
TSINGTAO BREWERY H YC 1 Action
VARTA AG
VARTA AG Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025